Long-Term Management Issues in Restless Legs Syndrome

被引:11
作者
Chokroverty, Sudhansu [1 ,2 ,3 ,4 ]
机构
[1] Seton Hall Univ, Dept Neurol, S Orange, NJ 07079 USA
[2] Seton Hall Univ, Dept Neurophysiol & Sleep Med, S Orange, NJ 07079 USA
[3] Seton Hall Univ, Dept Neurosci, S Orange, NJ 07079 USA
[4] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, Newark, NJ 07103 USA
关键词
restless legs syndrome augmentation; akathisia; impulse control disorders; sleep attacks; rebound; tolerance; DOPAMINE DYSREGULATION SYNDROME; LIMB MOVEMENT-DISORDER; DOUBLE-BLIND TRIAL; OPEN-LABEL; SYNDROME RLS; PRAMIPEXOLE TREATMENT; SYNDROME AUGMENTATION; PRACTICE PARAMETERS; SLEEP DURATION; FOLLOW-UP;
D O I
10.1002/mds.23652
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Restless legs syndrome is a neurologic movement and sleep disorder with lifelong symptoms causing considerable morbidity. Several short-term and some long-term open-label and double-blind clinical trials have demonstrated the efficacy and safety of dopaminergic treatment in restless legs syndrome. Long-term treatment, however, is associated with the emergence of vexing long-term side effects that pose a challenge for physicians. These long-term complications can be broadly categorized as disease-related (impact on sleep and acute exacerbation of restless legs syndrome symptoms), and medication issues (augmentation, sleep attacks, impulse control disorders, addiction and dependence, site reaction, occasionally sleep apnea, fibrotic complications, and weight gain). (C) 2011 Movement Disorder Society
引用
收藏
页码:1378 / 1385
页数:8
相关论文
共 93 条
[1]   At-risk for pathological gambling: imaging neural reward processing under chronic dopamine agonists [J].
Abler, Birgit ;
Hahlbrock, Roman ;
Unrath, Alexander ;
Groen, Georg ;
Kassubek, Jan .
BRAIN, 2009, 132 :2396-2402
[2]  
AKPINER S, 1982, ARCH NEUROL-CHICAGO, V13, P739
[3]   Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome [J].
Allen, R ;
Becker, PM ;
Bogan, R ;
Schmidt, M ;
Kushida, CA ;
Fry, JM ;
Poceta, JS ;
Winslow, D .
SLEEP, 2004, 27 (05) :907-914
[4]  
ALLEN R, 2009, SLEEP MED S, V10, pS82
[5]   Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J].
Allen, RP ;
Picchietti, D ;
Hening, WA ;
Trenkwalder, C ;
Walters, AS ;
Montplaisi, J .
SLEEP MEDICINE, 2003, 4 (02) :101-119
[6]   Restless legs syndrome prevalence and impact - REST general population study [J].
Allen, RP ;
Walters, AS ;
Montplaisir, J ;
Hening, W ;
Myers, A ;
Bell, TJ ;
Ferini-Strambi, L .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (11) :1286-1292
[7]   Augmentation of the restless legs syndrome with carbidopa/levodopa [J].
Allen, RP ;
Earley, CJ .
SLEEP, 1996, 19 (03) :205-213
[8]   Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome [J].
Allen, RP ;
Mignot, E ;
Ripley, B ;
Nishino, S ;
Earley, CJ .
NEUROLOGY, 2002, 59 (04) :639-641
[9]  
ALLEN RP, 2010, ACUTE EMERGENT EVENT, P130
[10]   Rotigotine transdermal patch - In restless legs syndrome [J].
Baldwin, Claudine M. ;
Keating, Gillian M. .
CNS DRUGS, 2008, 22 (10) :797-806